ArticleDiscover oncology2025
Impact of differential detection of TM6SF2 rs58542926 mutation in circulating tumor DNA versus peripheral blood cells on hepatocellular carcinoma patients.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the differential distribution of the genotypes of the TM6SF2 rs58542926 polymorphism in circulating tumor DNA (ctDNA) versus peripheral blood cells (PBMC) and its association with the development of hepatocellular carcinoma (HCC) in patients infected with the hepatitis C virus (HCV) in Egypt. A total of 147 HCC patients were enrolled in the study, and their genomic and ctDNA were analyzed for the TM6SF2 rs58542926 genotype. The CC genotype was identified as the most common among patients with HCC in Egypt, while the CT genotype was associated with higher serum direct bilirubin, total leucocyte count, and hemoglobin levels than those with the CC genotype. Circulating samples from patients with the CT genotype had significantly higher serum direct bilirubin, ALT, and prothrombin time than those with the CC genotype, as well as a significantly higher percentage of smokers, alcohol intake, and HCV PCR-positive patients. Our findings suggest that lifestyle factors such as smoking and alcohol intake may contribute to the development of HCC in patients with the CT genotype. Both genomic and ctDNA for the TM6SF2 rs58542926 genotype complemented and correlated with parameters of chronic liver disease and underlying risk factors for HCC. Circulating DNA for gene polymorphism provided additional real-time information and more value in correlation with the worsening of liver condition and the presence of HCC risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.